ZA201802451B - 2,4-dihydroxy-nicotinamides as apj agonists - Google Patents

2,4-dihydroxy-nicotinamides as apj agonists

Info

Publication number
ZA201802451B
ZA201802451B ZA2018/02451A ZA201802451A ZA201802451B ZA 201802451 B ZA201802451 B ZA 201802451B ZA 2018/02451 A ZA2018/02451 A ZA 2018/02451A ZA 201802451 A ZA201802451 A ZA 201802451A ZA 201802451 B ZA201802451 B ZA 201802451B
Authority
ZA
South Africa
Prior art keywords
nicotinamides
dihydroxy
apj agonists
apj
agonists
Prior art date
Application number
ZA2018/02451A
Other languages
English (en)
Inventor
Soong-Hoon Kim
Hannguang J Chao
Heather Finlay
Ji Jiang
James A Johnson
R Michael Lawrence
Michael C Myers
Monique Phillips
George O Tora
Wei Meng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201802451B publication Critical patent/ZA201802451B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2018/02451A 2015-10-14 2018-04-13 2,4-dihydroxy-nicotinamides as apj agonists ZA201802451B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241367P 2015-10-14 2015-10-14
US201562270659P 2015-12-22 2015-12-22
PCT/US2016/056769 WO2017066402A1 (en) 2015-10-14 2016-10-13 2,4-dihydroxy-nicotinamides as apj agonists

Publications (1)

Publication Number Publication Date
ZA201802451B true ZA201802451B (en) 2020-01-29

Family

ID=57178558

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/02451A ZA201802451B (en) 2015-10-14 2018-04-13 2,4-dihydroxy-nicotinamides as apj agonists

Country Status (20)

Country Link
US (1) US10392347B2 (enExample)
EP (1) EP3362442B1 (enExample)
JP (1) JP6837482B2 (enExample)
KR (1) KR102707502B1 (enExample)
CN (1) CN108368087B (enExample)
AU (1) AU2016340264B2 (enExample)
BR (1) BR112018007395A2 (enExample)
CA (1) CA3001974A1 (enExample)
CL (1) CL2018000953A1 (enExample)
CO (1) CO2018004968A2 (enExample)
EA (1) EA034857B1 (enExample)
ES (1) ES2774945T3 (enExample)
IL (1) IL258577B (enExample)
MX (1) MX376824B (enExample)
PE (1) PE20181197A1 (enExample)
SG (1) SG10201908839QA (enExample)
TW (1) TW201720796A (enExample)
UY (1) UY36949A (enExample)
WO (1) WO2017066402A1 (enExample)
ZA (1) ZA201802451B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573936B2 (en) 2015-05-20 2017-02-21 Amgen Inc. Triazole agonists of the APJ receptor
SMT201900427T1 (it) 2015-06-03 2019-09-09 Bristol Myers Squibb Co Agonisti di apj a base di 4-idrossi-3-(eteroaril)piridin-2-one per l'uso nel trattamento di disturbi cardiovascolari
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
SG11201804674UA (en) 2015-12-16 2018-06-28 Bristol Myers Squibb Co Heteroarylhydroxypyrimidinones as agonists of the apj receptor
ES2895124T3 (es) 2016-03-24 2022-02-17 Bristol Myers Squibb Co 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
KR102521956B1 (ko) * 2016-10-14 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541804B1 (en) 2016-11-16 2025-01-22 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2025153720A1 (en) * 2024-01-19 2025-07-24 Scenic Biotech Bv Pla2g15 inhibitors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH602664A5 (en) 1973-06-14 1978-07-31 Sandoz Ag 2-Tert. amino-alkylamino-pyrimidine derivs.
ZA835878B (en) * 1982-08-23 1985-03-27 Warner Lambert Co Cardiotonic agents
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
DE4425616A1 (de) * 1994-07-20 1996-01-25 Basf Ag Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
EP1301490A2 (en) 2000-07-18 2003-04-16 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
JP2006508030A (ja) 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド ピリミジノン化合物、組成物および方法
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050197327A1 (en) 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US8367845B2 (en) 2006-04-21 2013-02-05 The Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
JP2007308441A (ja) * 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
EP2079707B1 (de) 2006-10-10 2014-12-03 proionic GmbH & Co KG Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US20110253929A1 (en) 2008-12-22 2011-10-20 Basf Se Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors
US9040538B2 (en) 2009-05-21 2015-05-26 Universite Laval Pyrimidines as novel therapeutic agents
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
EP2714698B1 (en) 2011-05-31 2016-11-09 Merck Patent GmbH Compounds containing hydrido-tricyano-borate anions
TW201311709A (zh) 2011-05-31 2013-03-16 Merck Patent Gmbh 電解質配方
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014004676A1 (en) 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
DK2897939T3 (en) * 2012-09-21 2017-05-08 Sanofi Sa BENZOIMIDAZOLCARBOXYL ACID AMIDE DERIVATIVES FOR THE TREATMENT OF METABOLIC OR CARDIOVASCULAR DISEASES
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
HUE043705T2 (hu) 2013-06-27 2019-09-30 Pfizer Heteroaromás vegyületek és dopamin D1 ligandumként történõ alkalmazásuk
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
WO2015079028A1 (de) 2013-11-29 2015-06-04 Vtu Holding Gmbh Verrfahren zum aushärten eines klebstoffs mittels mikrowellenbestrahlung
WO2015184011A2 (en) 2014-05-28 2015-12-03 Sanford-Burnham Medical Research Institute Agonists of the apelin receptor and methods of use thereof
JP6767878B2 (ja) * 2014-06-06 2020-10-14 リサーチ トライアングル インスティテュート アペリン受容体（ａｐｊ）アゴニストおよびそれらの使用
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
DK3287443T3 (da) 2015-04-24 2022-02-07 Shionogi & Co 6-leddet heterocyklisk derivat og farmaceutisk sammensætning, som omfatter dette
US9573936B2 (en) 2015-05-20 2017-02-21 Amgen Inc. Triazole agonists of the APJ receptor
SMT201900427T1 (it) 2015-06-03 2019-09-09 Bristol Myers Squibb Co Agonisti di apj a base di 4-idrossi-3-(eteroaril)piridin-2-one per l'uso nel trattamento di disturbi cardiovascolari
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
SG11201804674UA (en) 2015-12-16 2018-06-28 Bristol Myers Squibb Co Heteroarylhydroxypyrimidinones as agonists of the apj receptor
ES2895124T3 (es) 2016-03-24 2022-02-17 Bristol Myers Squibb Co 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
KR102521956B1 (ko) 2016-10-14 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제

Also Published As

Publication number Publication date
KR102707502B1 (ko) 2024-09-13
WO2017066402A1 (en) 2017-04-20
JP2018530591A (ja) 2018-10-18
US20180297954A1 (en) 2018-10-18
PE20181197A1 (es) 2018-07-23
IL258577B (en) 2020-07-30
CN108368087A (zh) 2018-08-03
MX376824B (es) 2025-03-07
EA034857B1 (ru) 2020-03-30
IL258577A (en) 2018-05-31
SG10201908839QA (en) 2019-10-30
CL2018000953A1 (es) 2018-08-24
EP3362442A1 (en) 2018-08-22
EA201890858A1 (ru) 2018-09-28
KR20180067599A (ko) 2018-06-20
ES2774945T3 (es) 2020-07-23
MX2018004344A (es) 2018-05-01
AU2016340264A1 (en) 2018-05-31
TW201720796A (zh) 2017-06-16
CO2018004968A2 (es) 2018-10-10
JP6837482B2 (ja) 2021-03-03
US10392347B2 (en) 2019-08-27
BR112018007395A2 (pt) 2018-10-23
UY36949A (es) 2017-04-28
CN108368087B (zh) 2022-04-12
AU2016340264B2 (en) 2021-01-07
CA3001974A1 (en) 2017-04-20
EP3362442B1 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
IL288232A (en) 1,7- naphthyridine as immunomodulators
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
ZA201806356B (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
ZA201807350B (en) Novel compounds as gpr119 agonists
GB201507594D0 (en) Intamac 1
IL247773A0 (en) Pyridine-2-carboxamides 5,6-dimuters as cannabinoid receptor antagonists
SG11201703479SA (en) Substituted 2,4 diamino-quinoline as new anticancer agents
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
IL258217A (en) 2,3,4,5 tetrahydropyridin-6-amine derivatives
HK1255164A1 (en) 2,4-dihydroxy-nicotinamides as apj agonists
HK40002893A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
GB201519732D0 (en) Mrbr.2
AU5457P (en) JOAe 6656 Aeonium arborium
GB201500297D0 (en) Agonists
HK1253837A1 (en) Substituted 1,2-dihydro-3h
GB201521485D0 (en) .
GB201518402D0 (en) Products, uses & methods (8)
GB201510891D0 (en) Products, uses & methods (7)
GB201509366D0 (en) Products, uses & methods (6)
GB201507774D0 (en) Products, uses & methods (2)
GB201507773D0 (en) Products, uses & methods (1)
GB201507776D0 (en) Products, uses & methods (4)
GB201507775D0 (en) Products, uses & methods (3)
GB201503680D0 (en) Whatyouwearing.com
GB201513785D0 (en) Aerocar 1